Verastem, Inc. (VSTM) News
Filter VSTM News Items
VSTM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VSTM News Highlights
- For VSTM, its 30 day story count is now at 3.
- Over the past 5 days, the trend for VSTM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RAMP and SAFE are the most mentioned tickers in articles about VSTM.
Latest VSTM News From Around the Web
Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsBOSTON, December 18, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics ("GenFleet"). |
3 Off-the-Beaten-Path Stocks Poised for Substantial GrowthAs horror film fans know, there’s safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. |
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerBOSTON, December 13, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). |
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside PotentialIf the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. |
3 Penny Stocks to Buy to Turn $1 into $100: November 2023Are you looking for outsized gains for your portfolio. |
All You Need to Know About Verastem (VSTM) Rating Upgrade to BuyVerastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment ApproachBOSTON, November 13, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of the new healthcare professional component of Let’s Talk About LGSOC, designed to support clinicians in the diagnosis and management of low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about the unique clinical, histopathological, and molecular features of LGSOC, current N |
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBOSTON, November 08, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress. |
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian CancerBOSTON, November 07, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced results of the first-ever LGSOC Patient Impact Survey that reveal the particular challenges with diagnosis, disease management and mental, physical, and emotional well-being experienced by people living with low-grade serous ovarian cancer (LGSOC)*.1 This multi-national, online survey was conducted by The Harris Poll on behalf of |
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient PopulationBOSTON, November 06, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy. The results of this planned subgroup analysis of Part A of the Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial were presented as a late-breaking abstract in an oral p |